Mechanisms underlying the inhibitory effects of lipopolysaccharide on human platelet adhesion.
Alterations in platelet aggregation in septic conditions are well established. However, little is known about the effects of lipopolysaccharide (LPS) on platelet adhesion. We have therefore investigated the effects of LPS in human platelet adhesion, using an in vitro model of platelet adhesion to fibrinogen-coated wells. Microtiter plates were coated with human fibrinogen, after which washed platelets (6 x 10(8) platelets/ml) were allowed to adhere. Adherent platelets were quantified through measurement of acid phosphatase activity. Calcium mobilization in Fura2-AM-loaded platelets was monitored with a spectrofluorimeter. Platelet flow cytometry in thrombin-stimulated platelets was performed using monoclonal mouse anti-platelet GPIIb/IIIa antibody (PAC-1). Prior incubation of washed platelets with LPS (0.01-300 microg/ml) for 5 to 60 min concentration- and time-dependently inhibited non-activated platelet adhesion. In thrombin-activated (50 mU/ml) platelets, LPS inhibited the adhesion to a significantly lesser extent than non-activated platelets. Cyclohexamide, superoxide dismutase polyethylene glycol (PEG-SOD) or catalase polyethylene glycol did not affect the LPS responses. No alterations in cyclic GMP levels were seen after platelet incubation with LPS, except with the highest concentration employed (300 microg/ml) where an increase of 36% (P < 0.05) was observed. Thrombin increased by 7.5-fold the internal Ca(2+) platelet levels, an effect markedly inhibited by LPS. Thrombin induced concentration-dependent platelet GPIIb/IIIa activation, but LPS failed to affect the activation state of this membrane glycoprotein. In conclusion, LPS inhibits human platelet adhesion to fibrinogen by mechanisms involving blockade of external Ca(2+), independently of cGMP generation and activation of GPIIb/IIIa complex.
Morganti
Rafael P
RP
Department of Pharmacology, State University of Campinas (UNICAMP), Campinas (SP), Brazil.
Cardoso
Marcia H M
MH
Pereira
Fernanda G
FG
Lorand-Metze
Irene
I
De Nucci
Gilberto
G
Marcondes
Sisi
S
Antunes
Edson
E
D000135:Acid Phosphatase / Q000378:metabolism; D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D002118:Calcium / Q000378:metabolism; D002374:Catalase / Q000378:metabolism; D002478:Cells, Cultured; D006152:Cyclic GMP / Q000378:metabolism; D003513:Cycloheximide / Q000378:metabolism; D054641:Dual Specificity Phosphatase 2 / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology*; D051379:Mice; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010979:Platelet Function Tests; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000378:metabolism; D011500:Protein Synthesis Inhibitors / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism
D008070:Lipopolysaccharides; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011500:Protein Synthesis Inhibitors; D017382:Reactive Oxygen Species; D005340:Fibrinogen; D003513:Cycloheximide; D002374:Catalase; D013482:Superoxide Dismutase; D000135:Acid Phosphatase; C517032:DUSP2 protein, human; D054641:Dual Specificity Phosphatase 2; D006152:Cyclic GMP; D002118:Calcium